Monitoring a Hypothetical Channelopathy in Chronic Fatigue Syndrome

References

• Holmes G, Kaplan J, Gantz J, et al. Chronic Fatigue Syndrome: a working case definition. Ann Intern Med 1988; 108: 387–389.
   PubMed Web of Science ®Google Scholar
• Fukuda K, Straus S, Hickie I, et al. The Chronic Fatigue Syndrome: a compre-hensive approach to its definition and study. Ann Intern Med 1994; 121: 953–959.
   PubMed Web of Science ®Google Scholar
• De Meirleir K, Bisbal C, Campine I, et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med 2000; 108: 99–105.
   PubMed Web of Science ®Google Scholar
• Englebienne P, Herst CV, De Smet K, et al. Interactions between RNase L ankyrin-like domain and ABC transportres as a possible origin for pain, ion transport, CNS and immune disorders of Chronic Fatigue Immune Dysfunction Syndrome. J Chronic Fatigue Syndr 2001; 8(3/4): 83–102.
   Google Scholar
• Chaudhuri A, Behan PO. Neurological dyfunction in chronic fatigue syndrome. J Chronic Fatigue Syndr 2000; 6(3/4): 51–68.
   Google Scholar
• Watson WS, McMillan DC, Chaudhuri A, et al. Increased resting energy expen-diture in the chronic fatigue syndrome. J Chronic Fatigue Syndr 1998; 4: 3–14.
   Google Scholar
• Burnet RB, Yeap BB, Chatterton BE, et al. Chronic fatigue syndrome: is total body potassium important? Med J Aust 1996; 164: 384.
   PubMed Web of Science ®Google Scholar
• Flynn MA, Nolph GB, Krause G. Comparison of body composition measured by total body potassium and infrared interactance. J Am Coll Nutr 1995; 14: 652–5.
   Google Scholar
• Schaefer F, Georgi M, Zieger A, et al. Usefulness of bioelectric impedance and skinfold measurements in predicting fat-free mass derived from total body potassium in children. Pediatr Res 1994; 35: 617–624.
   PubMed Web of Science ®Google Scholar
• Cohn SH, Dombrowski CS. Absolute measurement of whole-body potassium by gamma-ray spectrometry. J Nucl Med 1970; 11: 239–46.
   PubMed Web of Science ®Google Scholar
• Suhadolnik RJ, Peterson DL, O'Brien K, et al. Biochemical evidence for a novel molecular weight 2-5A-dependent RNase L in Chronic Fatigue Syndrome. J In-terferon Cytokine Res 1997; 17: 377–385.
   Google Scholar
• Dewaide PA, Lefebure P, Van Cauwenberge H, et al. Determination du potas-sium total par anthropogammamétrie. Quelques applications en pathologie interne. Acta Clin Be1g1970; 25: 193–214.
   Google Scholar
• Bennett V, Otto E, Kunimoto M, et al. Diversity of ankyrins in the brain. Biochem Soc Trans 1991; 19: 1034–1039.
   PubMed Web of Science ®Google Scholar
• Bisbal C, Martinand C, Silhol M, et al. Cloning and characterization of a RNase L inhibitor. J Biol Chem 1995; 270: 13308–13317.
   PubMed Web of Science ®Google Scholar
• Sherwood L. Human physiology: from cells to systems. Belmont: Wadsworth Publishing Company. 1997. p. 491.
   Google Scholar
• Sanz JM, Di Vergilio F. Kinetics and mechanism of ATP-dependent IL-1f3 re-lease from microglial cells. J Immunol 2000; 164: 4893–4898.
   PubMed Web of Science ®Google Scholar
• Levite M, Cahalon L, Peretz A, et al. Extracellular K+ and opening of volt-age-gated potassium channels activate T cell integrin function: physical and functional association between Kv1.3 channels andf31 integrins. J Exp Med 2000; 191: 1167–1176.
   Google Scholar
• Lai Z-F, Chen Y-Z, Nishimura Y, et al. An amiloride- sensitive and voltage-de-pendent Na+ channel in an HLA-DR-restricted human T-cell clone. J Immunol 2000; 165: 83–90.
   Google Scholar
• Linde A, Andersson B, Svensson SB, et al. Serum levels of lymphokines and soluble cellular receptors in primary EBV infection and in patients with chronic fatigue syndrome. J Infect Dis 1992; 165: 994–1000.
   PubMed Web of Science ®Google Scholar
• Patarca R, Klimas NG, Lutgendorf S, et al. Dysregulated expression of tumor necrosis factor in Chronic Fatigue Syndrome, interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis 1994; 18: S147–153.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Gandevia S, Brockman A, et al. Cytokine production and fatigue in patients with chronic fatigue syndrome and healthy control subjects in response to ex-ercise. Clin Infect Dis 1994; 18: Si 5142–6.
   Google Scholar
• Peakman M, Deale A, Field R, et al. Clinical improvement in Chronic Fatigue Syndrome is not associated with lymphocyte subsets of function or activation. Clin Immunol Immunopathol 1997; 82: 83–91.
   PubMedGoogle Scholar
• Fanger CM, Rauer H, Neben AL, et al. Calcium-activated potassium channels sustain calcium signalling in T lymphocytes. J Biol Chem 2001; 276: 12249–12256.
   PubMed Web of Science ®Google Scholar
• Haverstick DM, Dicus M, Resnick MS, et al. A role for protein kinase Cf3I in the regulation of Ca2+ entry in Jurkat T cells. J Biol Chem 1997; 272: 15426–15433.
   PubMed Web of Science ®Google Scholar
• Gardner P. Calcium and T lymphocyte activation. Cell 1989; 59: 15–20.
   PubMed Web of Science ®Google Scholar
• Hosfield CM, Elce JS, Davies PL, et al. Crystal structure of calpain reveals the structural basis for Ca2+-dependent protease activity and a novel mode of enzyme acti-vation. EMBO J 1999; 18: 6880–6889.
   PubMed Web of Science ®Google Scholar
• Mehmet H. Caspases find a new place to hide. Nature 2000; 403: 29–30.
   PubMedGoogle Scholar
• Zhang Q, Zhou X-D, Denny T, et al. Changes in immune parameters seen in gulf war veterans but not in civilians with Chronic Fatigue Syndrome. Clin Diagn Lab Immunol 1999; 6: 6–13.
   Google Scholar
• Levine PH, Whiteside TL, Friberg D, et al. Dysfunction of natural killer cell ac-tivity in a family with chronic fatigue syndrome. Clin Immunol Immunopathol 1998; 88: 99–104.
   Google Scholar
• Whiteside TL, Friberg D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med 1998; 105: 27S–34S.
   Google Scholar
• Mawle AC, Nisenbaum R, Dobbins JG, et al. Immune responses associated with chronic fatigue syndrome: a case-control study. J Infect Dis 1997; 175: 136–41.
   PubMed Web of Science ®Google Scholar
• Tirelli U, Marotta G, Improta S, et al. Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol 1994; 40: 601–8.
   PubMed Web of Science ®Google Scholar
• Morrison LJ, Behan WH, Behan PO. Changes in natural killer cell phenotype in patients with post-viral fatigue syndrome. Clin Exp Immunol 1991; 83: 441–6.
   Google Scholar
• Klimas NG, Salvato FR, Morgan R, et al. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28: 1403–10.
   PubMed Web of Science ®Google Scholar
• Preedy VR, Smith DG, Salisbury JR, et al. Biochemical and muscle studies in patients with acute onset post-viral fatigue syndrome. J Clin Pathol 1993; 46: 722–6.
   PubMed Web of Science ®Google Scholar
• Herst CV, De S met K, D'Haene A, et al. The interaction of RNase L ankyrin do-main with ABC transporters might explain pain and many of the physiological disor-ders of CFS. Abstract presented at the AACFS fifth international research, clinical and patient conference. Abstract book page 71.
   Google Scholar